Cargando…
Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia
BACKGROUND: Very few studies have compared the effects and side effects of vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. This study aimed to compare the efficacy and safety of vancomycin and teicoplanin in patients with methicillin-resistant Staph...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264637/ https://www.ncbi.nlm.nih.gov/pubmed/35799129 http://dx.doi.org/10.1186/s12879-022-07549-2 |
_version_ | 1784743005256679424 |
---|---|
author | Lee, Jang Ho Choi, Myeong Geun Park, Hyung Jun Kim, Ho Cheol Choi, Chang-Min |
author_facet | Lee, Jang Ho Choi, Myeong Geun Park, Hyung Jun Kim, Ho Cheol Choi, Chang-Min |
author_sort | Lee, Jang Ho |
collection | PubMed |
description | BACKGROUND: Very few studies have compared the effects and side effects of vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. This study aimed to compare the efficacy and safety of vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. METHODS: This study examined 116 patients with methicillin-resistant Staphylococcus aureus pneumonia who met the inclusion criteria and were treated with either vancomycin (n = 54) or teicoplanin (n = 62). The primary (i.e., clinical failure during treatment) and secondary outcomes (i.e., mortality rates, discontinuation of study drugs due to treatment failure, side effects, and clinical cure) were evaluated. RESULTS: The vancomycin group presented lower clinical failure rates (25.9% vs. 61.3%, p < 0.001), discontinuation due to treatment failure (22.2% vs. 41.9%, p = 0.024), and mortality rates (3.7% vs 19.4%, p = 0.010). The Cox proportional hazard model revealed that teicoplanin was a significant clinical failure predictor compared with vancomycin (adjusted odds ratio, 2.198; 95% confidence interval 1.163–4.154). The rates of drug change due to side effects were higher in the vancomycin group than in the teicoplanin group (24.1% vs. 1.6%, p < 0.001). CONCLUSIONS: Vancomycin presented favorable treatment outcomes and more side effects compared with teicoplanin, which suggests that clinicians would need to consider the efficacy and potential side effects of these drugs before prescription. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07549-2. |
format | Online Article Text |
id | pubmed-9264637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92646372022-07-09 Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia Lee, Jang Ho Choi, Myeong Geun Park, Hyung Jun Kim, Ho Cheol Choi, Chang-Min BMC Infect Dis Research Article BACKGROUND: Very few studies have compared the effects and side effects of vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. This study aimed to compare the efficacy and safety of vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. METHODS: This study examined 116 patients with methicillin-resistant Staphylococcus aureus pneumonia who met the inclusion criteria and were treated with either vancomycin (n = 54) or teicoplanin (n = 62). The primary (i.e., clinical failure during treatment) and secondary outcomes (i.e., mortality rates, discontinuation of study drugs due to treatment failure, side effects, and clinical cure) were evaluated. RESULTS: The vancomycin group presented lower clinical failure rates (25.9% vs. 61.3%, p < 0.001), discontinuation due to treatment failure (22.2% vs. 41.9%, p = 0.024), and mortality rates (3.7% vs 19.4%, p = 0.010). The Cox proportional hazard model revealed that teicoplanin was a significant clinical failure predictor compared with vancomycin (adjusted odds ratio, 2.198; 95% confidence interval 1.163–4.154). The rates of drug change due to side effects were higher in the vancomycin group than in the teicoplanin group (24.1% vs. 1.6%, p < 0.001). CONCLUSIONS: Vancomycin presented favorable treatment outcomes and more side effects compared with teicoplanin, which suggests that clinicians would need to consider the efficacy and potential side effects of these drugs before prescription. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07549-2. BioMed Central 2022-07-07 /pmc/articles/PMC9264637/ /pubmed/35799129 http://dx.doi.org/10.1186/s12879-022-07549-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Lee, Jang Ho Choi, Myeong Geun Park, Hyung Jun Kim, Ho Cheol Choi, Chang-Min Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia |
title | Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia |
title_full | Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia |
title_fullStr | Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia |
title_full_unstemmed | Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia |
title_short | Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia |
title_sort | comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant staphylococcus aureus pneumonia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264637/ https://www.ncbi.nlm.nih.gov/pubmed/35799129 http://dx.doi.org/10.1186/s12879-022-07549-2 |
work_keys_str_mv | AT leejangho comparisonofmortalityandclinicalfailureratesbetweenvancomycinandteicoplanininpatientswithmethicillinresistantstaphylococcusaureuspneumonia AT choimyeonggeun comparisonofmortalityandclinicalfailureratesbetweenvancomycinandteicoplanininpatientswithmethicillinresistantstaphylococcusaureuspneumonia AT parkhyungjun comparisonofmortalityandclinicalfailureratesbetweenvancomycinandteicoplanininpatientswithmethicillinresistantstaphylococcusaureuspneumonia AT kimhocheol comparisonofmortalityandclinicalfailureratesbetweenvancomycinandteicoplanininpatientswithmethicillinresistantstaphylococcusaureuspneumonia AT choichangmin comparisonofmortalityandclinicalfailureratesbetweenvancomycinandteicoplanininpatientswithmethicillinresistantstaphylococcusaureuspneumonia |